Company Profile

Immuron Limited (NASDAQ: IMRN)
5:30 PM UTC, 07/03/24
Last: $2.02 Change: -0.14 %Change: -6.52% Volume: 18,714
Detailed Quote
Open: $ 2.09   Volume: 18,714
High: $ 2.20   Yield(%) 0.00
Low: $ 1.96   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 12.31M
EPS ($) n/a   Shares Out: 5.70M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -6.04
% Price Change (last 13 weeks): -19.96
% Price Change (last 26 weeks): 13.74
% Price Change (last 52 weeks): 10.82
% Price Change (year to date): 15.20
Management Effectiveness
Return on Equity (%): -17.57
Return on Assets (%): -16.05
Return on Invested Capital (%): -31.51
Profitability
Gross Profit Margin (%): 72.54
Net Profit Margin (%): -209.81
Operating Profit Margin (%): -332.49
Price & Volume
50-day Moving Average: $2.31
200-day Moving Average: $2.06
Avg. Daily Vol. (last 50 days): 6,240
Avg. Daily Vol. (last 200 days): 287,792
52-wk high: $5.96
52-wk low: $1.48
Bid: $2.08
Ask: $2.80
Company Information
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.
Immuron Limited
62 Lygon Street Level 3
Carlton VI 3053

Phone: 61.3.9824.5254
Fax: n/a
http://www.immuron.com
Per Share Data
Earnings (1year) ($): -0.45
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 2.29
Cash Flow ($): -0.44
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): 9.48
Price/Book (x): 0.88
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 8.82
Current Ratio (x): 9.20
LT Debt/Equity (x): 0.77
Total Debt/Equity (x): 0.96



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.